Afimmune - pioneering drug discovery in rare and cardiometabolic diseases

About Afimmune

Afimmune, headquartered in Dublin, Ireland, is a drug discovery and development company working on new medicines to improve the quality of life for people with rare and inflammatory diseases. Afimmune has assets in various stages of clinical and pre-clinical development. Afimmune pipeline

Latest News

November 5, 2025

Afimmune to host session before and present at the 67th American Society of Hematology (ASH) Annual Meeting after completing Sickle Cell Disease trial enrolment.

Dublin, Ireland, 5 November 2025: Afimmune, a clinical stage biopharmaceutical company developing novel rare disease therapeutics, today announced that enrolment has successfully completed in the first clinical trial […]

More Press Releases

Publications and Conferences

May 13, 2022

EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE

Presentation during EHA2022: All (e)Poster presentations will be made available as of Friday, June 10, 2022 (09:00 CEST) and will be accessible for on-demand viewing until […]

Join our mailing list

Contact us

t: +353 1 2946380 e: [email protected]